Contact
searchSearch
HMP Global
Login

Head & Neck Squamous Cell Carcinoma

Head & Neck Squamous Cell Carcinoma
Excellence Forum
Leaders in the field sharing authoritative insights and institutional best practices.

Catherine Haring, MD
Videos
Using ctDNA to Guide Treatment in HPV-Positive Oropharyngeal Cancer
04/29/2026
Catherine Haring, MD
Catherine Haring, MD, discusses findings from a study evaluating ctDNA as a biomarker in patients with HPV-related oropharyngeal cancer undergoing surgery.
Catherine Haring, MD, discusses findings from a study evaluating ctDNA as a biomarker in patients with HPV-related oropharyngeal cancer undergoing surgery.
Catherine Haring, MD, discusses...
04/29/2026
Oncology
Annu Singh, MD
Videos
Risk of Osteoradionecrosis in Patients With Oral Cavity Cancer Undergoing Radiation Therapy
03/17/2026
Annu Singh, MD
Annu Singh, MD, discusses results from a retrospective cohort study comparing incidence of late-term osteoradionecrosis in patients with oral cavity cancer undergoing intensity-modulated and proton radiation therapy.
Annu Singh, MD, discusses results from a retrospective cohort study comparing incidence of late-term osteoradionecrosis in patients with oral cavity cancer undergoing intensity-modulated and proton radiation therapy.
Annu Singh, MD, discusses...
03/17/2026
Oncology
Edward Christopher Dee, MD
Videos
Radiation Modality Influences Risk of Osteoradionecrosis in Head and Neck Cancer
03/17/2026
Edward Christopher Dee, MD
Edward Christopher Dee, MD, discusses results from a retrospective cohort study evaluating osteoradionecrosis risk in patients with oropharyngeal cancers treated with either proton or intensity-modulated radiation therapy.
Edward Christopher Dee, MD, discusses results from a retrospective cohort study evaluating osteoradionecrosis risk in patients with oropharyngeal cancers treated with either proton or intensity-modulated radiation therapy.
Edward Christopher Dee, MD,...
03/17/2026
Oncology
Ranee Mehra, MD
Videos
First-Line Amivantamab Plus Pembrolizumab in HPV-Negative Head and Neck Squamous Cell Carcinoma
03/05/2026
Ranee Mehra, MD
Ranee Mehra, MD, discusses results from cohort 2 of the phase 1b/2 OrigAMI-4 study, which evaluated first-line subcutaneous amivantamab plus pembrolizumab in HPV-negative, PD-L1–positive head and neck squamous cell carcinoma.
Ranee Mehra, MD, discusses results from cohort 2 of the phase 1b/2 OrigAMI-4 study, which evaluated first-line subcutaneous amivantamab plus pembrolizumab in HPV-negative, PD-L1–positive head and neck squamous cell carcinoma.
Ranee Mehra, MD, discusses...
03/05/2026
Oncology
Thomas Roberts, MD, MBA
Videos
Tumor-Informed ctDNA MRD Assay May Predict Recurrence and Survival Outcomes in HPV-Independent Head and Neck Cancer
03/05/2026
Thomas Roberts, MD, MBA
Thomas Roberts, MD, MBA, shared study results which analyzed a tumor-informed ctDNA-based MRD assay in primarily HPV-independent, locally advanced head and neck squamous cell carcinoma.
Thomas Roberts, MD, MBA, shared study results which analyzed a tumor-informed ctDNA-based MRD assay in primarily HPV-independent, locally advanced head and neck squamous cell carcinoma.
Thomas Roberts, MD, MBA, shared...
03/05/2026
Oncology
Janice Huang and Alex Reznik
Videos
Identifying Systemic Barriers to Clinical Trial Completion in Head and Neck Cancer
02/11/2026
Alex Reznik; Janice Huang
A case-control analysis of 346 head and neck squamous cell carcinoma trials found that early termination is frequently driven by non-scientific, strategic decisions, especially in industry- and government-sponsored studies.
A case-control analysis of 346 head and neck squamous cell carcinoma trials found that early termination is frequently driven by non-scientific, strategic decisions, especially in industry- and government-sponsored studies.
A case-control analysis of 346...
02/11/2026
Oncology
Eric Mastrolonardo, MD
Videos
Pathologic Response After Neoadjuvant Immunotherapy Correlates With Disease-Free Survival in Head and Neck Cancer
01/26/2026
Eric Mastrolonardo, MD
Eric Mastrolonardo, MD, discusses findings from a systematic review and meta-analysis evaluating whether pathologic treatment response after neoadjuvant immune checkpoint inhibition is associated with survival outcomes in resectable mucosal...
Eric Mastrolonardo, MD, discusses findings from a systematic review and meta-analysis evaluating whether pathologic treatment response after neoadjuvant immune checkpoint inhibition is associated with survival outcomes in resectable mucosal...
Eric Mastrolonardo, MD,...
01/26/2026
Oncology
Lauren Miller, MD
Videos
Real-World Considerations for Perioperative Pembrolizumab in Locally Advanced Head and Neck Squamous Cell Carcinoma
01/21/2026
Lauren Miller, MD
Lauren Miller, MD, discusses real-world challenges and opportunities of pembrolizumab use in patients with advanced PD-L1–positive head and neck squamous cell carcinoma.
Lauren Miller, MD, discusses real-world challenges and opportunities of pembrolizumab use in patients with advanced PD-L1–positive head and neck squamous cell carcinoma.
Lauren Miller, MD, discusses...
01/21/2026
Oncology
Benjamin Kann, MD
Videos
AI-Predicted Extranodal Extension Improves Risk Stratification in Oropharyngeal Carcinoma
01/14/2026
Benjamin Kann, MD
Benjamin Kann, MD, discusses results from a large retrospective study evaluating an automated AI-based imaging platform to predict extranodal extension in patients with oropharyngeal carcinoma using pretreatment CT scans.
Benjamin Kann, MD, discusses results from a large retrospective study evaluating an automated AI-based imaging platform to predict extranodal extension in patients with oropharyngeal carcinoma using pretreatment CT scans.
Benjamin Kann, MD, discusses...
01/14/2026
Oncology
Emma Connolly, MB BCh BAO
Videos
Redefining “High Risk” for Patients With Cutaneous Squamous Cell Carcinoma of the Head and Neck
10/21/2025
Emma Connolly, MB, BCh, BAO
Emma Connolly, MB BCh BAO, discusses an analysis which identified a distinct high-risk subgroup of patients with cutaneous squamous cell carcinoma of the head and neck who had inferior disease-free survival following postoperative...
Emma Connolly, MB BCh BAO, discusses an analysis which identified a distinct high-risk subgroup of patients with cutaneous squamous cell carcinoma of the head and neck who had inferior disease-free survival following postoperative...
Emma Connolly, MB BCh BAO,...
10/21/2025
Oncology

Recent News

FDA Alerts
Capivasertib Gains Support from the FDA’s Advisory Committee in Metastatic Hormone-Sensitive Prostate Cancer
05/04/2026
Stephanie Holland
Based on results from the phase 3 CAPItello-281 trial, the FDA’s Oncologic Drugs Advisory Committee has voted that capivasertib plus abiraterone and ADT demonstrates a favorable benefit-risk profile in PTEN-deficient metastatic...
Based on results from the phase 3 CAPItello-281 trial, the FDA’s Oncologic Drugs Advisory Committee has voted that capivasertib plus abiraterone and ADT demonstrates a favorable benefit-risk profile in PTEN-deficient metastatic...
Based on results from the phase...
05/04/2026
Oncology
FDA Approval
FDA Approves Vepdegestrant for Patients With ER-Positive, HER2-Negative, ESR1-Mutated Advanced or Metastatic Breast Cancer
05/01/2026
Emily Estrada
Based on results from the phase 3 VERITAC-2 trial, the FDA has approved vepdegestrant for patients with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer.
Based on results from the phase 3 VERITAC-2 trial, the FDA has approved vepdegestrant for patients with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer.
Based on results from the phase...
05/01/2026
Oncology
News
Varegacestat Advances Toward FDA Review in Desmoid Tumors
04/30/2026
Stephanie Holland
Based on results from the phase 3 RINGSIDE trial, a New Drug Application for varegacestat has been submitted to the FDA for the treatment of adult patients with desmoid tumors.
Based on results from the phase 3 RINGSIDE trial, a New Drug Application for varegacestat has been submitted to the FDA for the treatment of adult patients with desmoid tumors.
Based on results from the phase...
04/30/2026
Oncology
News
Nirogacestat Improves Outcomes Across Prognostic Subgroups of Patients With Desmoid Tumors
04/30/2026
Stephanie Holland
Results from a post hoc analysis of the phase 3 DeFi trial demonstrate that nirogacestat provides consistent clinical benefit across prognostic subgroups of patients with desmoid tumors.
Results from a post hoc analysis of the phase 3 DeFi trial demonstrate that nirogacestat provides consistent clinical benefit across prognostic subgroups of patients with desmoid tumors.
Results from a post hoc analysis...
04/30/2026
Oncology
News
FOG-001 Shows Early Activity in Patients With Desmoid Tumors
04/30/2026
Stephanie Holland
Results from a phase 1/2 study demonstrate that FOG-001 shows early clinical activity with manageable safety in patients with desmoid tumors.
Results from a phase 1/2 study demonstrate that FOG-001 shows early clinical activity with manageable safety in patients with desmoid tumors.
Results from a phase 1/2 study...
04/30/2026
Oncology
News
Bireociclib Plus Fulvestrant in HR-Positive, HER2-Negative Advanced Breast Cancer
04/30/2026
Emily Estrada
Final results from the phase 3 BRIGHT-2 trial demonstrated that bireociclib plus fulvestrant significantly improves PFS compared with fulvestrant alone in previously treated HR-positive, HER2-negative advanced breast cancer.
Final results from the phase 3 BRIGHT-2 trial demonstrated that bireociclib plus fulvestrant significantly improves PFS compared with fulvestrant alone in previously treated HR-positive, HER2-negative advanced breast cancer.
Final results from the phase 3...
04/30/2026
Oncology
News
Romiplostim Reduces the Need for Dose Modifications in Chemotherapy-Induced Thrombocytopenia
04/30/2026
Emily Estrada
Results from the phase 3 RECITE trial demonstrated that romiplostim significantly reduced the need for chemotherapy dose modifications in patients with chemotherapy-induced thrombocytopenia.
Results from the phase 3 RECITE trial demonstrated that romiplostim significantly reduced the need for chemotherapy dose modifications in patients with chemotherapy-induced thrombocytopenia.
Results from the phase 3 RECITE...
04/30/2026
Oncology
News
Tri-Weekly Cisplatin Matches Weekly Dosing With Better Tolerability in Cervical Cancer
04/30/2026
Stephanie Holland
Results from the phase 3 TACO trial demonstrate that tri-weekly cisplatin provides similar survival with improved safety and quality of life vs weekly dosing in patients with locally advanced cervical cancer.
Results from the phase 3 TACO trial demonstrate that tri-weekly cisplatin provides similar survival with improved safety and quality of life vs weekly dosing in patients with locally advanced cervical cancer.
Results from the phase 3 TACO...
04/30/2026
Oncology
FDA Alerts
FDA Grants Breakthrough Therapy Designation to TERN-701 in Ph-Positive Chronic Myeloid Leukemia
04/30/2026
Stephanie Holland
Based on data from the phase 1/2 CARDINAL study, the FDA has granted breakthrough therapy designation to TERN-701 for previously treated Ph-positive chronic myeloid leukemia.
Based on data from the phase 1/2 CARDINAL study, the FDA has granted breakthrough therapy designation to TERN-701 for previously treated Ph-positive chronic myeloid leukemia.
Based on data from the phase 1/2...
04/30/2026
Oncology
News
HSK42360 Shows Clinical Promise in BRAF V600-Mutant Glioma
04/29/2026
Emily Estrada
Results from a phase 1 study demonstrate that HSK42360 shows promising clinical activity with favorable safety in patients with BRAF V600-mutant gliomas.
Results from a phase 1 study demonstrate that HSK42360 shows promising clinical activity with favorable safety in patients with BRAF V600-mutant gliomas.
Results from a phase 1 study...
04/29/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use